IQWiG: Industry transparency pledge to publish Phase III trials "still falls short"
This article was originally published in Scrip
Executive Summary
A recent commitment by the International Federation of Pharmaceutical Manufacturers and Associations, the IFPMA, and its members, to submitting the results of all industry-sponsored Phase III clinical trials for publication in scientific peer-reviewed journals in a bid to improve transparency does not go far enough to prevent publication bias, says IQWiG, Germany's health technology appraisal institute.